MWM
NBIX icon

Moran Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Moran Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.52M Buy
50,557
+27,051
+115% +$4.01M 0.23% 143
2026
Q1 		$3.1M Buy
+23,506
New +$3.12M 0.09% 263

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Moran Wealth Management's NBIX Position: Q2 2026 in Review

Moran Wealth Management increased its Neurocrine Biosciences (NBIX) stake by 115% in Q2 2026, buying an estimated $4.01M and bringing the position to 50,557 shares worth $8.52M. The position accounts for 0.23% of the portfolio, ranked #143.

Moran Wealth Management first reported a position in NBIX in Q1 2026 and has held it in 2 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Moran Wealth Management held 50,557 shares of Neurocrine Biosciences worth $8.52M as of Q2 2026.
  • Moran Wealth Management bought 27,051 Neurocrine Biosciences shares in Q2 2026, an estimated $4.01M.
  • Neurocrine Biosciences made up 0.23% of Moran Wealth Management's portfolio in Q2 2026, its #143 holding.
  • Moran Wealth Management first reported a position in Neurocrine Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Moran Wealth Management's 13F filing for Q2 2026, filed 5 Aug 2026.